Pharmaceuticals - Union Register

  

Register of orphan medicinal products


GRANTED  

Product information

Exendin (9-39)

EU orphan designation number: EU/3/16/1750   
Active ingredient: Exendin (9-39)
Indication: Treatment of noninsulinoma pancreatogenous hypoglycaemia syndrome
Sponsor: Eiger Biopharmaceuticals Europe Limited
30 Upper High Street, Thame, Oxon, OX9 3EZ, United Kingdom

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
18/10/2016 Orphan designation EMA/OD/065/16 (2016)6741 of 14/10/2016